Steve Matt's avatar
$1.2m follower assets
$OM $STAA $SILK Earnings: What I'm Looking For
Outset Medical, Inc. ($OM) - Reporting earnings Wednesday (5/4) afternoon
The company revolutionizing home dialysis. I'm very excited about the future of this company.

Here's what I'm looking for:

  • 100% revenue growth may not be sustainable but I'd love to see >50%.
  • Gross profit margins >12%
  • Update from management of Tablo demand (# of units deployed and backlogged).

Current position:
Total cost basis: 65th highest in my portfolio
Time since first buy: 1.34 years
Number of purchases since: 3
Annualized return: (26.9%)
Annualized $SPY return: 6.5%
Annualized $QQQ return: (0.8%)


STAAR Surgical Company ($STAA) - Reporting earnings Wednesday (5/4) afternoon
Ooh boy, has STAAR contracted on their multiples. Regardless, they continue to innovate. On March 28, they announced FDA approval for the EVO/EVO+ Visian® Implantable Collamer® Lens for the correction of myopia and myopia with astigmatism and 9 days later announced the first US implant. This lens has already been available outside the US. The US was just 4.3% of their $230MM. The runway is long.

Here's what I'm looking for:

  • Nothing crazy here. Just looking for revenue growth to maintain or accelerate, the company to continue being FCF, and margins maintaining or improving.
  • I hope management gives an update on the order backlog of over 20,000 lens that was caused by COVID and supply chain constraints.

Current position:
Total cost basis: 80th highest in my portfolio
Time since first buy: 0.69 years
Number of purchases since: 0
Annualized return: (69.2%)
Annualized $SPY return: (10.4%)
Annualized $QQQ return: (20.1%)


Silk Road Medical, Inc ($SILK) - Reporting earnings Wednesday (5/4) afternoon
Just two days ago Silk Road announced the FDA approval of expanded indications for the ENROUTE® Transcarotid Stent System. I didn't understand the full implications of this so I showed my doctor wife and she said it's a big deal. I guess that's why Silk Road was up 14% of Monday.

Here's what I'm looking for:

  • Same as STAA. Nothing crazy here. Just looking for revenue growth to maintain or accelerate, margins maintaining or improving, maybe a movement towards being FCF positive.
  • Quarterly updates on the number procedures performed would be a nice change of pace.

Current position:
Total cost basis: 80th highest in my portfolio
Time since first buy: 0.69 years
Number of purchases since: 1
Annualized return: (28.7%)
Annualized $SPY return: (10.3%)
Annualized $QQQ return: (20.0%)
No comments yetBe the first to add your insight!

Author

Related